The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Open accessPublished version of a preprint
Abstract
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2 1-5. Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC 50 values) as low as 2 ng ml-1. In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of these NAb responses appear to correlate with viral load, with higher responses reported in patients with more severe disease, and in older adults compared with younger adults26–29.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In agreement with previous reports3,6,9, there was a broad range of plasma neutralizing activity 3–14 weeks after the second vaccine dose that was similar to that elicited by natural infection in a convalescent cohort after 1.3 months, and greater than the activity at 6.2 months after infection (Fig. 1a, Extended Data Table 1).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SARS-CoV-2 infection rapidly elicits nAbs (16, 21–24) that decline, but remain detectable, over several months (25–29).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spike is the target of SARS-CoV-2 neutralizing antibodies, and the receptor binding domain (RBD) of Spike is the target of >90% of neutralizing antibodies in COVID-19 cases (Brouwer et al., 2020; Piccoli et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Suthar et al., 2020), with some neutralizing antibodies instead targeting the N-terminal domain (NTD) (Liu et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although it is unclear how long protective effects last beyond the first few months after vaccination, some studies suggest that the elicited neutralizing activity is maintained for up to 8 months after the natural infection with SARS-CoV-2 (refs. 41,42).”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [41]
Experimental — accuracy not yet measured
In the citing paper
“8 weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers3,5,6.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“In line with previous reports3,6,9, IgG and IgM levels were significantly higher in the vaccinated group compared to a cohort of convalescent patients assayed 1.3 and 6.2 months after infection, while IgA levels were similar (Extended Data Fig 1j–l).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [6]
In the citing paper
“We limited our analysis to RBD because plasma RBD antibodies are strongly correlated with neutralizing activity3,10–12.”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Consistent with this observation, there was an overall increase in the apparent avidity of plasma antibodies between 1.3 and 12 months3,4 (P < 0.0001) (Extended Data Fig. 7c).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [3]
In the citing paper
“Most serum nAb responses elicited during natural infection are directed at the RBD (21, 23, 30, 31).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Numerous neutralizing anti-RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, 22–24, 32–37).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [23]
In the citing paper
“Analyses of the B cell responses to the spike generally focus on the RBD and on cells sorted with RBD baits introducing an inherent bias by omitting non-RBD targets”
From SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“The neutralizing antibodies are produced by B cells with a wide range of heavy chain and light chain V genes (Robbiani et al., 2020; Rogers et al., 2020). SARS-CoV-2 neutralizing antibodies also exhibit little to no somatic hypermutation (Gaebler et al., 2020; Robbiani et al., 2020; Rogers et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“Although neutralizing antibody titers have not correlated with reduced COVID-19 severity (Dan et al., 2021; Piccoli et al., 2020; Robbiani et al., 2020), SARS-CoV-2 cTfh cell frequencies have been associated with reduced disease severity (Rydyznski Moderbacher et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“This appears to hold true in the case of SARS-CoV-2, where neutralizing antibody titers (and total Spike antibody titers) have positively correlated with COVID-19 disease severity in large cohort studies (Piccoli et al., 2020; Robbiani et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
In the citing paper
“However, it should also be noted that circulating SARS-CoV-2 neutralizing antibody titers are relatively low in a substantial fraction of recovered COVID-19 cases (Dan et al., 2021; Robbiani et al., 2020; Wajnberg et al., 2020), indicating that either the neutralizing antibody potency or the serum concentration is suboptimal in this subset.”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Robbiani et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,927
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,136
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T. M., Willey, R. L., Rabson, A. B., & Martín, M. Á. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,805
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Cited by
Sorted by citations
Items 901–1,000 of 1,017
Aiello, A., Grossi, A., Meschi, S., Meledandri, M., Vanini, V., Petrone, L., Casetti, R., Cuzzi, G., Salmi, A., Altera, A. M. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920227 · Cited by 18
Boorla, V. S., Chowdhury, R., Ramasubramanian, R., Ameglio, B., Frick, R., Gray, J. J., & Maranas, C. D. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26422 · Cited by 18
Yang, X., Chi, H., Wu, M., Wang, Z., Lang, Q., Han, Q., Wang, X., Liu, X., Li, Y., Wang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992787 · Cited by 18
Self-citationImmune repertoire sequencing reveals an abnormal adaptive immune system in COVID‐19 survivors
Chen, J., Zhou, Z., Pan, W., Zhang, P., Yang, M., Zhao, M., Li, B., Liu, P., Zhang, Q., Kong, X., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28340 · Cited by 18
Self-citationCheng, Y., Shen, P., Tao, Y., Zhang, W., Xu, B., Bi, Y., Han, Z. Y., & Zhou, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1025901 · Cited by 18
Andreev, A. I., Andreev, I. V., Nechay, K. O., Esaulova, D. R., Baklakova, O. S., Vecherko, V. I., Shilovskiy, I. P., Кофиади, И. А., Гудима, Г. О., Martynov, A. I., et al. (2022) · Immunologiya · doi:10.33029/0206-4952-2022-43-5-583-592 · Cited by 18
Prodrug Rewards in Medicinal Chemistry: An Advance and Challenges Approach for Drug Designing
Husain, A., Monga, J., Narwal, S., Singh, G., Rashid, M., Afzal, O., Alatawi, A., & Al-Madani, N. M. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301169 · Cited by 18
Bloom, N. I., Ramirez, S. I., Cohn, H., Parikh, U. M., Heaps, A., Sieg, S. F., Greninger, A. L., Ritz, J., Moser, C., Eron, J. J., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae371 · Cited by 18
Paciello, I., Pierleoni, G., Pantano, E., Antonelli, G., Pileri, P., Maccari, G., Cardamone, D., Realini, G., Perrone, F., Neto, M. M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114645 · Cited by 18
Antibody sequence determinants of viral antigen specificity
Abu-Shmais, A. A., Vukovich, M. J., Wasdin, P. T., Suresh, Y. P., Marinov, T. M., Rush, S. A., Gillespie, R. A., Sankhala, R. S., Choe, M., Joyce, M. G., et al. (2024) · mBio · doi:10.1128/mbio.01560-24 · Cited by 18
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Chao, C. W., Sprouse, K. R., Miranda, M. C., Catanzaro, N., Hubbard, M. L., Addetia, A., Stewart, C., Brown, J. T., Dosey, A. M., Valdez, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115036 · Cited by 18
Devos, T., Geukens, T., Schauwvlieghe, A. F. A. D., Ariën, K. K., Barbezange, C., Cleeren, M., Compernolle, V., Dauby, N., Desmecht, D. J.-M., Grimaldi, D., et al. (2020) · Trials · doi:10.1186/s13063-020-04876-0 · Cited by 18
Kubo, S., Ohtake, N., Miyakawa, K., Jeremiah, S. S., Yamaoka, Y., Murohashi, K., Hagiwara, E., Mihara, T., Goto, A., Yamazaki, E., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.628281 · Cited by 18
Bell, B. N., Powell, A. E., Rodríguez, C., Cochran, J. R., & Kim, P. S. (2021) · Protein Science · doi:10.1002/pro.4044 · Cited by 18
Long Term Immune Response Produced by the SputnikV Vaccine
Martynova, E. V., Hamza, S., Garanina, E. E., Kabwe, E., Markelova, M., Shakirova, V. G., Хаертынова, И. М., Kaushal, N., Baranwal, M., Rizvanov, A. A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011211 · Cited by 18
Boelig, R. C., Chaudhury, S., Aghai, Z. H., Oliver, E. A., Mancuso, F., Berghella, V., & Bergmann‐Leitner, E. S. (2021) · AJOG Global Reports · doi:10.1016/j.xagr.2021.100046 · Cited by 18
Redox Homeostasis and Immune Alterations in Coronavirus Disease-19
Bellanti, F., Buglio, A. L., & Vendemiale, G. (2022) · Biology · doi:10.3390/biology11020159 · Cited by 18
Seow, J., Graham, C., Hallett, S. R., Lechmere, T., Maguire, T. J. A., Huettner, I., Cox, D., Khan, H., Pickering, S., Roberts, R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110757 · Cited by 18
Stewart, A., Sinclair, E. L., Ng, J. C.-F., O’Hare, J. S., Page, A., Serangeli, I., Margreitter, C., Orsenigo, F., Longman, K., Frampas, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807104 · Cited by 18
Evaluating the Immune Response in Treatment-Naive Hospitalised Patients With Influenza and COVID-19
Legebeke, J., Lord, J., Penrice-Randal, R., Vallejo, A. F., Poole, S., Brendish, N. J., Dong, X., Hartley, C. S., Holloway, J. W., Lucas, J. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.853265 · Cited by 18
Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations
Ma, J., Bai, H., Gong, T., Mao, W., Nie, Y., Zhang, X., Da, Y., Wang, X., Qin, H., Zeng, Q., et al. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.08.006 · Cited by 18
Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein
Chen, Y., Lin, J.-J., Ma, H., Zhong, N., Xie, X.-X., Yang, Y., Zheng, P., Zhang, L., Jin, T., & Cao, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810904 · Cited by 18
Advances in antibody discovery from human BCR repertoires
Xu, Z., Ismanto, H. S., Zhou, H., Saputri, D. S., Sugihara, F., & Standley, D. M. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.1044975 · Cited by 18
SARS-CoV-2 spike variants differ in their allosteric responses to linoleic acid
Oliveira, A. S. F., Shoemark, D. K., Davidson, A. D., Berger, I., Schaffitzel, C., & Mulholland, A. J. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad021 · Cited by 18
Bertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abasi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.03.409318 · Cited by 18
Rose, J., & McCullough, P. A. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101011 · Cited by 18
RetractedMustapha, J. O., Abdullahi, I. N., Ajagbe, O., Emeribe, A. U., Fasogbon, S. A., Onoja, S. O., Ugwu, C. E., Umeozuru, C. M., Ajayi, F. O., Tanko, W. N., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e05951 · Cited by 17
RetractedClinical Patterns and Morphology of COVID-19 Dermatology
Agnihothri, R. V., & Fox, L. P. (2021) · Dermatologic Clinics · doi:10.1016/j.det.2021.05.006 · Cited by 17
Monoclonal Antibodies Protect Aged Rhesus Macaques From SARS-CoV2 Induced Immune Activation
Verma, A., Hawes, C. E., Lakshmanappa, Y. S., Roh, J. W., Schmidt, B., Dutra, J., Louie, W., Liu, H., Ma, Z.-M., Watanabe, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109942 · Cited by 17
Self-citationLin, H., Chen, C.-C., Chiao, D.-J., Chang, T.-Y., Chen, X.-A., Young, J., & Kuo, S.-C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.020 · Cited by 17
Protein engineering responses to the COVID-19 pandemic
Hsieh, C., & McLellan, J. S. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102385 · Cited by 17
Nucleic Acid Vaccines against SARS-CoV-2
Liu, Y., & Ye, Q. (2022) · Vaccines · doi:10.3390/vaccines10111849 · Cited by 17
Synthetic nanobodies as tools to distinguish IgG Fc glycoforms
Kao, K. S., Gupta, A., Zong, G., Li, C., Kerschbaumer, I., Borghi, S., Achkar, J. M., Bournazos, S., Wang, L., & Ravetch, J. V. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212658119 · Cited by 17
Chernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37972-1 · Cited by 17
Zhao, Q., Wang, X., Zhang, Z., Liu, X., Wang, P., Cao, J. T., Liang, Q., Qu, J., & Zhou, M. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28932 · Cited by 17
Viral kinetics, stability and sensitivity analysis of the within-host COVID-19 model
Elbaz, I. M., El-Metwally, H. A., & Sohaly, M. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-38705-6 · Cited by 17
Gayvert, K. M., McKay, S., Lim, W. K., Baum, A., Kyratsous, C. A., Copin, R., & Atwal, G. S. (2023) · npj Viruses · doi:10.1038/s44298-023-00007-z · Cited by 17
Innovations and trends in antibody repertoire analysis
Townsend, D. R., Towers, D. M., Lavinder, J. J., & Ippolito, G. C. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103082 · Cited by 17
Li, H., Bian, Y., Liu, M., Lin, J., Dai, M., Xie, H., Yu, H., Chen, B., Xue, M., Li, Z., et al. (2024) · Resources Conservation and Recycling · doi:10.1016/j.resconrec.2024.107598 · Cited by 17
Kumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 17
Obesity-compromised immunity in post-COVID-19 condition: a critical control point of chronicity
Jang, S.-W., Hong, W., & Moon, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433531 · Cited by 17
Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020
Capai, L., Ayhan, N., Masse, S., Canarelli, J., Priet, S., Simeoni, M.-H., Charrel, R. N., de Lamballerie, X. N., & Falchi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113569 · Cited by 17
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
Guo, Y., Kawaguchi, A., Takeshita, M., Sekiya, T., Hirohama, M., Yamashita, A., the Keio Donner Project, Siomi, H., & Murano, K. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100346 · Cited by 17
Cross‐neutralization of RBD mutant strains of SARS‐CoV‐2 by convalescent patient derived antibodies
Lou, Y., Zhao, W., Wei, H., Chu, M. G., Chao, R., Yao, H., Su, J., Li, Y., Li, X., Cao, Y., et al. (2021) · Biotechnology Journal · doi:10.1002/biot.202100207 · Cited by 17
de Campos‐Mata, L., Vaquero, S. T., Tachó‐Piñot, R., Piñero, J., Grasset, E. K., Arrieta‐Aldea, I., Melero, N. R., Carolis, C., Horcajada, J. P., Cerutti, A., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1339 · Cited by 17
van der Straten, K., van Gils, M. J., de Taeye, S. W., & de Bree, G. J. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.867982 · Cited by 17
Shaheen, N. A., Sambas, R., Alenezi, M., Alharbi, N. K., Aldibasi, O. S., & Bosaeed, M. (2022) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_74_22 · Cited by 17
Potent neutralization by monoclonal human IgM against SARS‐CoV‐2 is impaired by class switch
Callegari, I., Schneider, M., Berloffa, G., Mühlethaler, T., Holdermann, S., Galli, E., Roloff, T. C., Boss, R., Infanti, L., Khanna, N., et al. (2022) · EMBO Reports · doi:10.15252/embr.202153956 · Cited by 17
Bergamaschi, C., Pagoni, M. N., Rosati, M., Angel, M., Tzannou, I., Vlachou, M., Darmani, I., Ullah, A., Bear, J., Devasundaram, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899972 · Cited by 17
MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection
Byrum, J. R., Waltari, E., Janson, O., Guo, S.-M., Folkesson, J., Chhun, B. B., Vinden, J., Ivanov, I. E., Forst, M. L., Li, H., et al. (2023) · Pathogens · doi:10.3390/pathogens12050671 · Cited by 17
Self-citationde Mattos Barbosa, M. G., Liu, H., Huynh, D., Shelley, G., Keller, E. T., Emmer, B. T., Sherman, E., Ginsburg, D., Kennedy, A. A., Tai, A. W., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147386 · Cited by 14
Survey of the current status of subclinical coronavirus disease 2019 (COVID-19)
Matsuba, I., Hatori, N., KOIDO, N., Watanabe, Y., Ebara, F., Matsuzawa, Y., Nishikawa, T., Kunishima, T., Degawa, H., Nishikawa, M., et al. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.09.005 · Cited by 16
Özgöçer, T., Daglı, S. N., Ceylan, M. R., Dişli, F., Uçar, C., & Yıldız, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27452 · Cited by 16
Latifi-Pupovci, H., Namani, S. A., Pajaziti, A., Ahmetaj‐Shala, B., Berisha, L. A., Kotori, A., Haxhibeqiri, V., Gegaj, V., & Bunjaku, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-09785-7 · Cited by 16
Rosati, M., Terpos, E., Bear, J., Burns, R. T., Devasundaram, S., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Dimopoulos, M. A., Pavlakis, G. N., et al. (2022) · Cancers · doi:10.3390/cancers14235816 · Cited by 16
Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
Pushparaj, P., Nicoletto, A., Dopico, X. C., Sheward, D. J., Kim, S., Ekström, S., Murrell, B., Corcoran, M., & Hedestam, G. B. K. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.1128253 · Cited by 16
Anti-SARS-CoV-2 Antibody Testing: Role and Indications
Mink, S., & Fraunberger, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247575 · Cited by 16
Bhattacharya, S., Jenkins, M. C., Keshavarz‐Joud, P., Bourque, A. R., White, K. M., Barkane, A. M. A., Bryksin, A. V., Hernández, C., Kopylov, M., & Finn, M. G. (2024) · ACS Nano · doi:10.1021/acsnano.4c00949 · Cited by 16
Successful simultaneous pancreas and kidney transplant in a patient post–COVID-19 infection
Singh, N. K., Tandukar, S., Zibari, G. B., Naseer, M. S., Amiri, H. S., & Samaniego, M. (2020) · Kidney International · doi:10.1016/j.kint.2020.09.004 · Cited by 16
Keshavarz, B., Wiencek, J. R., Workman, L. J., Straesser, M. D., Muehling, L. M., Canderan, G., Drago, F., Bonham, C. A., Sturek, J. M., Ramani, C., et al. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514203 · Cited by 16
Cohen, M. S., Wohl, D. A., Fischer, W. A., Smith, D. M., & Eron, J. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab494 · Cited by 16
Aparicio, B., Casares, N., Egea, J., Ruiz, M., Llópiz, D., Maestro, S., Olagüe, C., González‐Aseguinolaza, G., Smerdou, C., de Cerio, A. L.-D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1978823 · Cited by 16
Gu, M., Torres, J. L., Li, Y., Ry, A. V., Greenhouse, J. J., Wallace, S. M., Chiang, C.-I., Pessaint, L., Jackson, A. M., Porto, M., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1994354 · Cited by 16
Ferreira, C. D. S., Dantés, H. G., Bellei, N., López, E. L., Crespo, K. A. N., O’Ryan, M., & Villegas, J. (2021) · Viruses · doi:10.3390/v13122391 · Cited by 16
Khateeb, D. M., Gabrieli, T., Sofer, B., Hattar, A., Cordela, S., Chaouat, A. E., Spivak, I., Lejbkowicz, I., Almog, R., Mandelboim, M., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010242 · Cited by 16
Kolesov, D., Sinegubova, M. V., Dayanova, L. K., Dolzhikova, I. V., Vorobiev, I. I., & Orlova, N. A. (2022) · Diagnostics · doi:10.3390/diagnostics12020393 · Cited by 16
Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia
González, S. E., Regairaz, L., Salazar, M. R., Ferrando, N. S., González, V., Ramos, P. M. C., Pesci, S. A., Vidal, J. M., Kreplak, N., & Estenssoro, E. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002158 · Cited by 16
Lyski, Z. L., Brunton, A. E., Strnad, M., Sullivan, P. E., Siegel, S. A. R., Tafesse, F., Slifka, M. K., & Messer, W. B. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab585 · Cited by 16
Rotterdam, J., Thiaucourt, M., Weiß, C., Schwaab, J., Reiter, A., Kreil, S., Steiner, L., Fenchel, S., Popp, H. D., Hofmann, W., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04866-z · Cited by 16
COVID‐19, obesity, and immune response 2 years after the pandemic: A timeline of scientific advances
Belchior‐Bezerra, M., Lima, R. S., Medeiros, N. I., & Gomes, J. D. A. S. (2022) · Obesity Reviews · doi:10.1111/obr.13496 · Cited by 16
Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/31554 · Cited by 16
SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralizationPreprint
Jackson, L., Rodel, H. E., Hwa, S.-H., Cele, S., Ganga, Y., Tegally, H., Bernstein, M. P., Giandhari, J., COMMIT-KZN Team, Gosnell, B. I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.01.446516 · Cited by 16
Self-citationLung, T., Kazatchkine, M. D., Risch, L., Risch, M., & Nydegger, U. E. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102936 · Cited by 15
Schultz‐Cherry, S., McGargill, M. A., Thomas, P. G., Estepp, J. H., Gaur, A. H., Allen, E. K., Allison, K., Tang, L., Webby, R. J., Cherry, S., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab420 · Cited by 15
Dynamics of specific humoral response in COVID-19 patients
Zakurskayа, V. Y., Sizyakinа, L. P., Харитонова, М. В., & Shlyk, S. V. (2022) · Immunologiya · doi:10.33029/0206-4952-2022-43-1-71-77 · Cited by 15
SARS-CoV-2 epitopes inform future vaccination strategies
Shafqat, A., Omer, M. H., Ahmad, O., Niaz, M., Abdulkader, H. S., Shafqat, S., Mushtaq, A. H., Shaik, A., Elshaer, A. N., Kashir, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041185 · Cited by 15
Abdullahi, A., Frimpong, J. O., Cheng, M. T. K., Aliyu, S. H., Smith, C. J., Abimiku, A., Phillips, R. O., Owusu, M., & Gupta, R. K. (2023) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.23-0179 · Cited by 15
Su, H., Zhang, J., Yi, Z., Khan, S. U., Peng, M., Ye, L., Bao, A., Zhang, H., Suo, G., Li, Q., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.02.001 · Cited by 15
Yan, Q., Gao, X., Liu, B., Hou, R., He, P., Ma, Y., Zhang, Y., Zhang, Y., Li, Z., Chen, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51770-3 · Cited by 15
Picon, R. V., Carreno, I., da Silva, A. A., Mossmann, M., Laste, G., Domingues, G. D. C., Heringer, L. F. F., Gheno, B. R., Alvarenga, L. L., & Conte, M. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.028 · Cited by 15
Melgaço, J. G., Cunha, D. B. E., Azamor, T., da Silva, A. M. V., Tubarão, L. N., Gonçalves, R. B., Monteiro, R. Q., Missailidis, S., Neves, P., & Bom, A. P. D. A. (2020) · Journal of Immunology Research · doi:10.1155/2020/8827670 · Cited by 15
Patel, A. R., Reuschel, E. L., Xu, Z., Zaidi, F. I., Kim, K. Y., Scott, D. P., Mendoza, J. M., Ramos, S. J., Stoltz, R., Feldmann, F., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146082 · Cited by 15
The Immunopathobiology of SARS-CoV-2 Infection
Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 15
SARS-CoV-2 and Plasma Hypercoagulability
Steadman, E., Fandaros, M., & Yin, W. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00685-w · Cited by 15
B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
Nasonov, E. L., & Avdeeva, A. S. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-384-393 · Cited by 15
Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans
Goyal, K., Goel, H., Baranwal, P., Tewary, A., Dixit, A., Pandey, A. K., Benjamin, M., Tanwar, P., Dey, A., Khan, F., et al. (2021) · Immuno · doi:10.3390/immuno1040032 · Cited by 15
Cheng, Z. J., Li, B., Zhan, Z., Zhao, Z., Xue, M., Zheng, P., Lyu, J., Hu, C., He, J., Chen, R., et al. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08912-y · Cited by 15
Schuh, A. J., Satheshkumar, P. S., Dietz, S., Bull–Otterson, L., Charles, M. D., Edens, C., Jones, J. M., Bajema, K. L., Clarke, K. E. N., McDonald, L. C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01247-22 · Cited by 15
SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
Terahara, K., Sato, T., Adachi, Y., Tonouchi, K., Onodera, T., Moriyama, S., Sun, L., Takano, T., Nishiyama, A., Kawana‐Tachikawa, A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104959 · Cited by 15
New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15502 · Cited by 15
Nan, J., Sun, W., Liu, X., Che, Y., Shan, H., Yue, Y., Liu, J., Wang, L., Liu, K., Xu, W., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03732 · Cited by 15
Humoral immunity for durable control of SARS-CoV-2 and its variants
Kotaki, R., Moriyama, S., & Takahashi, Y. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00255-9 · Cited by 15
Beaudoin-Bussières, G., Tauzin, A., Dionne, K., Gendron‐Lepage, G., Medjahed, H., Perreault, J., Levade, I., Alfadhli, L., Bo, Y., Bazin, R., et al. (2023) · Viruses · doi:10.3390/v15061274 · Cited by 15
Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine
Thames, A. H., Wolniak, K. L., Stupp, S. I., & Jewett, M. C. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00644 · Cited by 15
Beddingfield, B. J., Maness, N. J., Fears, A. C., Rappaport, J., Aye, P. P., Russell‐Lodrigue, K., Doyle‐Meyers, L. A., Blair, R. V., Carias, A. M., Madden, P. J., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.753444 · Cited by 15
Ainsua‐Enrich, E., Pedreño-López, N., Bracke, C., Ávila‐Nieto, C., de la Concepción, M. L. R., Pradenas, E., Trinité, B., Marfil, S., Miranda, C., González, S. M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105455 · Cited by 14
Limoges, M.-A., Quenum, A., Chowdhury, M. M. H., Rexhepi, F., Namvarpour, M., Akbari, S. A., Rioux‐Perreault, C., Nandi, M., Lucier, J., Lemaire‐Paquette, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223936 · Cited by 14
Rodríguez‐Ubreva, J., Calafell-Segura, J., Calvillo, C. L., Keller, B., Ciudad, L., Handfield, L., de la Calle‐Fabregat, C., Godoy‐Tena, G., Andrés‐León, E., Hoo, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54732-x · Cited by 14
Olvera, À., Noguera-Julián, M., Kilpeläinen, A., Romero-Martín, L., Prado, J. G., & Brander, C. (2020) · Vaccines · doi:10.3390/vaccines8030444 · Cited by 14
The development of neutralizing antibodies against SARS-CoV-2 and their common features
Liu, L. D., Lian, C., Yeap, L.-S., & Meng, F. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa070 · Cited by 14
Metadata
- Authors
- Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hägglöf, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., Bianchini, F., Chen, S. T., Ramos, V., Patel, R., Dizon, J., Shimeliovich, I., Mendoza, P., Hartweger, H., Nogueira, L., Pack, M., Horowitz, J., Schmidt, F., Weisblum, Y., Michailidis, E., Ashbrook, A. W., Waltari, E., Pak, J. E., Huey-Tubman, K. E., Koranda, N., Hoffman, P. R., West, A. P., Rice, C. M., Hatziioannou, T., Bjorkman, P. J., Bieniasz, P. D., Caskey, M., & Nussenzweig, M. C.
- Affiliations
- Institute for Research in Biomedicine (CH)
- Rockefeller University (US)
- California Institute of Technology (US)
- Chan Zuckerberg Biohub San Francisco (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Robbiani, Davide F.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- ORCID
- Robbiani, Davide F.
- Gaebler, Christian
- Muecksch, Frauke
- Lorenzi, Julio C. C.
- Wang, Zijun
- Cho, Alice
- Agudelo, Marianna
- Barnes, Christopher O.
- Gazumyan, Anna
- Finkin, Shlomo
- Hägglöf, Thomas
- Oliveira, Thiago Y.
- Viant, Charlotte
- Hurley, Arlene
- Hoffmann, Hans-Heinrich
- Millard, Katrina G.
- Kost, Rhonda G.
- Cipolla, Melissa
- Bianchini, Filippo
- Chen, Spencer T.
- Dizon, Juan
- Shimeliovich, Irina
- Mendoza, Pilar
- Hartweger, Harald
- Nogueira, Lilian
- Schmidt, Fabian
- Weisblum, Yiska
- Michailidis, Eleftherios
- Ashbrook, Alison W.
- Waltari, Eric
- Pak, John E.
- Koranda, Nicholas
- Hoffman, Pauline R.
- West, Anthony P.
- Rice, Charles M.
- Bjorkman, Pamela J.
- Bieniasz, Paul D.
- Caskey, Marina
- Nussenzweig, Michel C.
- Venue
- Nature
- Published
- 2020-06-18
- Volume
- 584
- Issue
- 7821
- Pages
- 437-442
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7442695
- OpenAlex
- W3036386821
- Cited by
- 1,853
- References
- 47
- Citations by year
- 2026: 49 · 2025: 79 · 2024: 115 · 2023: 194 · 2022: 403 · 2021: 691 · 2020: 321
- FWCI
- 52.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute (UL1TR001866)
- George Mason University
- California Institute of Technology
- Fast Grants
- National Institutes of Health (P01-AI138398-S1, AI150464, TR001866, UL1TR001866)
- Beckman Institute, California Institute of Technology
- National Institute of Allergy and Infectious Diseases (R01AI091707, R01AI078788, P50AI150464, U19AI111825, P01AI138938, R37AI064003, T32AI070084)
- National Center for Advancing Translational Sciences (TR001866)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, convalescent plasma, neutralizing antibodies, receptor binding domain, spike protein, antibody response, memory B cells, pseudovirus neutralization, vaccine design, antibody epitopes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
